DCGI: 2 indigenous vaccines gets nod to start human trials

The Drug Controller General of India has granted nod to two indigenous candidate vaccines for Covid-19 for the commencement of early phase human trials in the country, said the Indian Council of Medical Research (ICMR).

Dr Balram Bhargava said that, “There are two Indian indigenous candidate vaccines. They have undergone successful toxicity studies in rats, mice and rabbits. The data was submitted to DCGI following which both these got clearance to start early phase human trials early this month. They have got their sites ready and they are doing their clinical study on approximately a thousand volunteers each at different sites,”

“The experiments for the two vaccines, among others, are also being done at NIV, Pune and spoke about the various programmes being carried out to develop a vaccine globally. Recently, Russia has fast-tracked a vaccine which has been successful in the early phases and they have fast-tracked its development. The whole world has applauded it and congratulated Russia. China has also fast-tracked its vaccine programme and fast-tracked its studies with vaccines. The US has again fast-tracked two of its vaccine candidates and the UK is also looking at how it can fastrack the Oxford vaccine candidate. Any vaccine produced in any party part of the world will ultimately have to be scaled up by India or by China. Because these are the two major vaccine producers of the world. Everyone who is trying to prepare a vaccine is in talks with India”, Bhargava added.

  • Related Posts

    Lupin Ramps Up Strategy to Counter U.S. Tariff Threat, Posts 52% Profit Surge

    Mumbai, August 7, 2025 — Indian pharmaceutical giant Lupin is drawing up a multi-pronged strategy to navigate the looming threat of U.S. tariffs, while celebrating a robust 52% year-on-year surge…

    Fortis Q1 Profit Jumps 57%; Expansion Drives Growth

      Gurugram, August 7 – http://Fortis HealthcareFortis Healthcare has reported a 57% year-on-year increase in its net profit for the first quarter of FY2025. The hospital chain posted ₹260 crore…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Piyush Goyal meets pharma industry leaders to discuss R&D, competitiveness boost

    Piyush Goyal meets pharma industry leaders to discuss R&D, competitiveness boost

    Senores Pharma to Buy Two Teva ANDAs

    Senores Pharma to Buy Two Teva ANDAs

    Lab-grown rabies antibodies show promise as cheaper, safer alternative

    Lab-grown rabies antibodies show promise as cheaper, safer alternative

    Lilly launches Mounjaro KwikPen in India

    Lilly launches Mounjaro KwikPen in India